skip navigation

Skip Nav

Clinical Guidelines Portal

skip navigation

Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

Management of Medication Toxicity or Intolerance

Hematologic Effects

(Last updated:2/12/2014; last reviewed:2/12/2014)

 Click here to view this table as an image

Table 11d. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations—Hematologic Effects
Adverse Effects Associated ARVs Onset/Clinical Manifestations Estimated Frequency Risk Factors Prevention/ Monitoring Management
Anemiaa Principally ZDV Onset:
  • Variable, weeks to months
Presentation
Most Commonly:
  • Asymptomatic or mild fatigue
  • Pallor
  • Tachypnea 
Rarely:
  • Congestive heart failure
HIV-Exposed Newborns:
  • Severe anemia uncommon, but may be seen coincident with physiologic Hgb nadir
HIV-Infected Children on ARVs:
  • 2–3 times more common with ZDV-containing regimens; less frequent with currently recommended dosing of ZDV
HIV-Exposed Newborns:
  • Premature birth
  • In utero exposure to ARVs
  • Advanced maternal HIV
  • Neonatal blood loss
  • Concurrent ZDV plus 3TC neonatal prophylaxis
HIV-Infected Children on ARVs:
  • Underlying hemoglobinopathy (sickle cell disease, G6PD deficiency)
  • Myelosuppressive drugs (e.g., TMP-SMX, rifabutin)
  • Iron deficiency
  • Advanced or poorly controlled HIV disease
HIV-Exposed Newborns:
  • Obtain CBC at birth.
  • Consider repeat CBC at 4 weeks for neonates who are at higher risk (e.g., those born prematurely or known to have low birth Hgb).
HIV-Infected Children on ARVs:
  • Avoid ZDV in children with moderate to severe anemia when alternative agents are available.
  • Obtain CBC as part of routine care.
HIV-Exposed Newborns:
  • Rarely require intervention unless Hgb is <7.0 g/dL or anemia is associated with symptoms.
  • Consider discontinuing ZDV if 4 weeks or more of a 6-week ZDV prophylaxis regimen are already completed (see the Perinatal Guidelinesb).
HIV-Infected Children on ARVs:
  • Discontinue non-ARV, marrow-toxic drugs, if feasible.
  • Treat coexisting iron deficiency, OIs, malignancies.
  • For persistent severe anemia thought to be associated with ARVs, change to a non-ZDV-containing regimen; consider a trial of erythropoietin if essential to continue ZDV.
Macrocytosis
Principally ZDV; also d4T
Onset:
  • Within days to weeks of starting therapy
  • MCV often >100 fL
Presentation:
  • Most often asymptomatic
  • Sometimes associated with anemia (occurs more often with ZDV than with d4T)
>90-95%, all ages
None Obtain CBC as part of routine care
None required unless associated with anemia
Neutropeniaa Principally
ZDV
Onset:
  • Variable
Presentation:
  • Most commonly asymptomatic. Complications appear to be less than with neutropenias associated with cancer chemotherapy.
HIV-Exposed Newborns:
  • Rare
HIV-Infected Children on ARVs:
  • 9.9%–26.8% of children on ARVs, depending upon the ARV regimen
  • Highest rates with ZDV-containing regimens
HIV-Exposed Newborns:
  • In utero exposure to ARVs
  • Concurrent ZDV plus 3TC neonatal prophylaxis
HIV-Infected Children on ARVs:
  • Advanced or poorly controlled HIV infection
  • Myelosuppressive drugs (e.g., TMP-SMX, ganciclovir, hydroxyurea, rifabutin)
HIV-Infected Children on ARVs:
  • Obtain CBC as part of routine care.
HIV-Exposed Newborns:
  • No established threshold for intervention; some experts would consider using an alternative NRTI for prophylaxis if ANC <500 cells/mm3, or discontinue ARV prophylaxis entirely if ≥4 weeks of 6-week ZDV prophylaxis have been completed (see the Perinatal Guidelinesb).
HIV-Infected Children on ARVs:
  • Discontinue non-ARV marrow-toxic drugs, if feasible.
  • Treat co-existing OIs and malignancies.
  • For persistent severe neutropenia thought to be associated with ARVs, change to a non-ZDV-containing regimen; consider a trial of G-CSF if essential to continue ZDV.
a HIV infection itself, OIs, and medications used to prevent OIs, such as TMP-SMX, may all contribute to anemia, neutropenia, and thrombocytopenia.
b Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States

Key to Acronyms: 3TC = lamivudine; ANC = absolute neutrophil count; ARV = antiretroviral; CBC = complete blood count; fL = femtoliter; G6PD = glucose-6-phosphate dehydrogenase; G-CSF = granulocyte colony-stimulating factor; Hgb = hemoglobin; NRTI = nucleoside reverse transcriptase inhibitor; OI = opportunistic infection; TMP-SMX = trimethoprim-sulfamethoxazole; ZDV = zidovudine

References

  1. Englund JA, Baker CJ, Raskino C, et al. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team. N Engl J Med. Jun 12 1997;336(24):1704-1712. Available at http://www.ncbi.nlm.nih.gov/pubmed/9182213.
  2. Starr SE, Fletcher CV, Spector SA, et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med. Dec 16 1999;341(25):1874-1881. Available at http://www.ncbi.nlm.nih.gov/pubmed/10601506.
  3. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. Nov 3 1994;331(18):1173-1180. Available at http://www.ncbi.nlm.nih.gov/pubmed/7935654.
  4. Krogstad P, Lee S, Johnson G, et al. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1. Clin Infect Dis. Apr 1 2002;34(7):991-1001. Available at http://www.ncbi.nlm.nih.gov/pubmed/11880966.
  5. McKinney RE, Jr., Johnson GM, Stanley K, et al. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team. J Pediatr. Oct 1998;133(4):500-508. Available at http://www.ncbi.nlm.nih.gov/pubmed/9787687.
  6. Najean Y, Rain JD. The mechanism of thrombocytopenia in patients with HIV infection. J Lab Clin Med. Mar 1994;123(3):415-420. Available at http://www.ncbi.nlm.nih.gov/pubmed/8133154.
  7. Caselli D, Maccabruni A, Zuccotti GV, et al. Recombinant erythropoietin for treatment of anaemia in HIV-infected children. AIDS. Jul 1996;10(8):929-931. Available at http://www.ncbi.nlm.nih.gov/pubmed/8828757.
  8. Allen UD, Kirby MA, Goeree R. Cost-effectiveness of recombinant human erythropoietin versus transfusions in the treatment of zidovudine-related anemia in HIV-infected children. Pediatr AIDS HIV Infect. Feb 1997;8(1):4-11. Available at http://www.ncbi.nlm.nih.gov/pubmed/11361510.
  9. Mueller BU, Jacobsen F, Butler KM, Husson RN, Lewis LL, Pizzo PA. Combination treatment with azidothymidine and granulocyte colony-stimulating factor in children with human immunodeficiency virus infection. J Pediatr. Nov 1992;121(5 Pt 1):797-802. Available at http://www.ncbi.nlm.nih.gov/pubmed/1279153.
  10. Bussel JB, Graziano JN, Kimberly RP, Pahwa S, Aledort LM. Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect. Blood. May 1 1991;77(9):1884-1893. Available at http://www.ncbi.nlm.nih.gov/pubmed/1850307.
  11. Scaradavou A, Woo B, Woloski BM, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood. Apr 15 1997;89(8):2689-2700. Available at http://www.ncbi.nlm.nih.gov/pubmed/9108386.
  12. Lahoz R, Noguera A, Rovira N, et al. Antiretroviral-related hematologic short-term toxicity in healthy infants: implications of the new neonatal 4-week zidovudine regimen. Pediatr Infect Dis J. Apr 2010;29(4):376-379. Available at http://www.ncbi.nlm.nih.gov/pubmed/19949355.
  13. Dryden-Peterson S, Shapiro RL, Hughes MD, et al. Increased risk of severe infant anemia after exposure to maternal HAART, Botswana. J Acquir Immune Defic Syndr. Apr 15 2011;56(5):428-436. Available at http://www.ncbi.nlm.nih.gov/pubmed/21266910.
  14. Mocroft A, Lifson AR, Touloumi G, et al. Haemoglobin and anaemia in the SMART study. Antivir Ther. 2011;16(3):329-337. Available at http://www.ncbi.nlm.nih.gov/pubmed/21555815.
  15. Nyesigire Ruhinda E, Bajunirwe F, Kiwanuka J. Anaemia in HIV-infected children: severity, types and effect on response to HAART. BMC Pediatr. 2012;12:170. Available at http://www.ncbi.nlm.nih.gov/pubmed/23114115.
  16. Esan MO, Jonker FA, Hensbroek MB, Calis JC, Phiri KS. Iron deficiency in children with HIV-associated anaemia: a systematic review and meta-analysis. Trans R Soc Trop Med Hyg. Oct 2012;106(10):579-587. Available at http://www.ncbi.nlm.nih.gov/pubmed/22846115.
  17. Nielsen-Saines K, Watts DH, Veloso VG, et al. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. N Engl J Med. Jun 21 2012;366(25):2368-2379. Available at http://www.ncbi.nlm.nih.gov/pubmed/22716975.